Christian Beyer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7333657/publications.pdf

Version: 2024-02-01

72 papers	5,531 citations	81839 39 h-index	91828 69 g-index
72 all docs	72 docs citations	72 times ranked	9694 citing authors

#	Article	IF	Citations
1	Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse. British Journal of Pharmacology, 2020, 177, 4296-4309.	2.7	19
2	PU.1 controls fibroblast polarization and tissue fibrosis. Nature, 2019, 566, 344-349.	13.7	121
3	Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators. Annals of the Rheumatic Diseases, 2018, 77, 459-459.	0.5	33
4	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. Annals of the Rheumatic Diseases, 2018, 77, 626-628.	0.5	12
5	The tyrosine phosphatase SHP2 controls TGFÎ²-induced STAT3 signaling to regulate fibroblast activation and fibrosis. Nature Communications, 2018, 9, 3259.	5.8	89
6	Pharmacological inhibition of porcupine induces regression of experimental skin fibrosis by targeting Wnt signalling. Annals of the Rheumatic Diseases, 2017, 76, 773-778.	0.5	22
7	Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. Annals of the Rheumatic Diseases, 2017, 76, 1133-1141.	0.5	66
8	Development of three-dimensional prints of arthritic joints for supporting patientsâ€™ awareness to structural damage. Arthritis Research and Therapy, 2017, 19, 34.	1.6	17
9	Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1941-1948.	0.5	149
10	Reports from the 2015 American College of Rheumatology Congress. Journal of Scleroderma and Related Disorders, 2016, 1, 16-20.	1.0	0
11	Inhibition of Notch1 promotes hedgehog signalling in a HES1-dependent manner in chondrocytes and exacerbates experimental osteoarthritis. Annals of the Rheumatic Diseases, 2016, 75, 2037-2044.	0.5	29
12	Educational needs and preferences of young European clinicians and physician researchers working in the field of rheumatology. RMD Open, 2016, 2, e000240.	1.8	14
13	Activating transcription factor 3 regulates canonical TGFÎ² signalling in systemic sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 586-592.	0.5	28
14	Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis. Annals of the Rheumatic Diseases, 2016, 75, 623-626.	0.5	78
15	Inactivation of autophagy ameliorates glucocorticoid-induced and ovariectomy-induced bone loss. Annals of the Rheumatic Diseases, 2016, 75, 1203-1210.	0.5	98
16	Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 883-890.	0.5	154
17	Inhibition of casein kinase II reduces TGFÎ² induced fibroblast activation and ameliorates experimental fibrosis. Annals of the Rheumatic Diseases, 2015, 74, 936-943.	0.5	45
18	Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFÎ² signalling. Annals of the Rheumatic Diseases, 2015, 74, 1408-1416.	0.5	92

#	Article	IF	Citations
19	Orphan nuclear receptor NR4A1 regulates transforming growth factor-Î² signaling and fibrosis. Nature Medicine, 2015, 21, 150-158.	15.2	267
20	Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies. Annals of the Rheumatic Diseases, 2015, 74, 1621-1625.	0.5	60
21	Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages. Annals of the Rheumatic Diseases, 2015, 74, 1317-1324.	0.5	28
22	S100A4 amplifies TGF-Î²-induced fibroblast activation in systemic sclerosis. Annals of the Rheumatic Diseases, 2015, 74, 1748-1755.	0.5	52
23	Vitamin D receptor regulates TGF-Î² signalling in systemic sclerosis. Annals of the Rheumatic Diseases, 2015, 74, e20-e20.	0.5	111
24	Deciphering the proâ€fibrotic phenotype of fibroblasts in systemic sclerosis. Experimental Dermatology, 2014, 23, 99-100.	1.4	5
25	The Nuclear Receptor Constitutive Androstane Receptor/NR1I3 Enhances the Profibrotic Effects of Transforming Growth Factor Î² and Contributes to the Development of Experimental Dermal Fibrosis. Arthritis and Rheumatology, 2014, 66, 3140-3150.	2.9	13
26	Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability. Annals of the Rheumatic Diseases, 2014, 73, 1264-1268.	0.5	32
27	The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Annals of the Rheumatic Diseases, 2014, 73, 1232-1239.	0.5	166
28	Inactivation of evenness interrupted (EVI) reduces experimental fibrosis by combined inhibition of canonical and non-canonical Wnt signalling. Annals of the Rheumatic Diseases, 2014, 73, 624-627.	0.5	26
29	Activation of pregnane X receptor inhibits experimental dermal fibrosis. Annals of the Rheumatic Diseases, 2013, 72, 621-625.	0.5	22
30	Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis. Archives of Dermatological Research, 2013, 305, 1-8.	1.1	25
31	Changing paradigms in spondylarthritis: The myofibroblast signature. Arthritis and Rheumatism, 2013, 65, 24-27.	6.7	7
32	Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. Annals of the Rheumatic Diseases, 2013, 72, 614-620.	0.5	93
33	Morphogen Pathways in Systemic Sclerosis. Current Rheumatology Reports, 2013, 15, 299.	2.1	23
34	Tyrosine kinase signaling in fibrotic disorders. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 897-904.	1.8	103
35	Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling. Annals of the Rheumatic Diseases, 2013, 72, 1575-1580.	0.5	69
36	Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis. Annals of the Rheumatic Diseases, 2013, 72, 1255-1258.	0.5	98

#	Article	IF	Citations
37	Modeling nuclear molecule release duringin vitrocell death. Autoimmunity, 2013, 46, 298-301.	1.2	16
38	Autophagy regulates TNFÎ±-mediated joint destruction in experimental arthritis. Annals of the Rheumatic Diseases, 2013, 72, 761-768.	0.5	249
39	A8.3â€...Deficit of S100A4 Prevents Joint Destruction and Systemic Bone Loss in hTNFtg Mouse Model. Annals of the Rheumatic Diseases, 2013, 72, A58.1-A58.	0.5	0
40	IgG4 immune response in Churgâ€“Strauss syndrome. Annals of the Rheumatic Diseases, 2012, 71, 390-393.	0.5	171
41	Innovative antifibrotic therapies in systemic sclerosis. Current Opinion in Rheumatology, 2012, 24, 274-280.	2.0	48
42	Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Annals of the Rheumatic Diseases, 2012, 71, 737-745.	0.5	53
43	Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. Annals of the Rheumatic Diseases, 2012, 71, 785-789.	0.5	73
44	Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Annals of the Rheumatic Diseases, 2012, 71, 1019-1026.	0.5	74
45	Pomalidomide is effective for prevention and treatment of experimental skin fibrosis. Annals of the Rheumatic Diseases, 2012, 71, 1895-1899.	0.5	31
46	Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1. Annals of the Rheumatic Diseases, 2012, 71, 2051-2054.	0.5	26
47	Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Blood, 2012, 120, 2909-2917.	0.6	53
48	Inhibition of sumoylation prevents experimental fibrosis. Annals of the Rheumatic Diseases, 2012, 71, 1904-1908.	0.5	28
49	Liver X receptors orchestrate osteoblast/osteoclast crosstalk and counteract pathologic bone loss. Journal of Bone and Mineral Research, 2012, 27, 2442-2451.	3.1	35
50	The extracellular release of DNA and HMGB1 from Jurkat T cells during inÂvitro necrotic cell death. Innate Immunity, 2012, 18, 727-737.	1.1	55
51	JAKâ€2 as a novel mediator of the profibrotic effects of transforming growth factor Î² in systemic sclerosis. Arthritis and Rheumatism, 2012, 64, 3006-3015.	6.7	115
52	Biomarkers of Fibrosis. , 2012, , 283-290.		0
53	Activation of canonical Wnt signalling is required for TGF-Î²-mediated fibrosis. Nature Communications, 2012, 3, 735.	5.8	649
54	Inhibition of activator protein 1 signaling abrogates transforming growth factor Î²â€“mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis and Rheumatism, 2012, 64, 1642-1652.	6.7	81

#	Article	IF	Citations
55	Î²-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Annals of the Rheumatic Diseases, 2012, 71, 761-767.	0.5	174
56	Strawberry gingivitis. Joint Bone Spine, 2012, 79, 322.	0.8	3
57	EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. Annals of the Rheumatic Diseases, 2011, 70, 1178-1182.	0.5	30
58	Inhibition of glycogen synthase kinase 3Â induces dermal fibrosis by activation of the canonical Wnt pathway. Annals of the Rheumatic Diseases, 2011, 70, 2191-2198.	0.5	96
59	Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Annals of the Rheumatic Diseases, 2011, 70, 1304-1310.	0.5	116
60	Microparticles stimulate angiogenesis by inducing ELR+ CXC-chemokines in synovial fibroblasts. Journal of Cellular and Molecular Medicine, 2011, 15, 756-762.	1.6	45
61	The prostaglandin E₂ system: A toolbox for skeletal repair?. Arthritis and Rheumatism, 2011, 63, 871-873.	6.7	4
62	Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis and Rheumatism, 2011, 63, 800-809.	6.7	73
63	Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis and Rheumatism, 2011, 63, 1396-1404.	6.7	107
64	Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Annals of the Rheumatic Diseases, 2011, 70, 1874-1875.	0.5	77
65	Platelet-derived serotonin links vascular disease and tissue fibrosis. Journal of Experimental Medicine, 2011, 208, 961-972.	4.2	222
66	Novel targets in bone and cartilage. Best Practice and Research in Clinical Rheumatology, 2010, 24, 489-496.	1.4	27
67	Animal models of systemic sclerosis: Prospects and limitations. Arthritis and Rheumatism, 2010, 62, 2831-2844.	6.7	135
68	The role of microparticles in the pathogenesis of rheumatic diseases. Nature Reviews Rheumatology, 2010, 6, 21-29.	3.5	232
69	Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?. Swiss Medical Weekly, 2010, 140, w13050.	0.8	26
70	Endothelial progenitor cells: Novel players in the pathogenesis of rheumatic diseases. Arthritis and Rheumatism, 2009, 60, 3168-3179.	6.7	39
71	Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Research and Therapy, 2009, 11, 220.	1.6	99
72	The scientific basis for novel treatments of systemic sclerosis. F1000 Medicine Reports, 2009, 1, .	2.9	3